Caris brings precision medicine assays closer to market

By staff writers

April 28, 2020 -- Caris Life Sciences has submitted premarket approval (PMA) applications to the U.S. Food and Drug Administration (FDA) for its MI Exome CDx and MI Transcriptome CDx assays.

MI Exome CDx for whole-exome sequencing (DNA) and MI Transcriptome CDx for whole transcriptome sequencing (RNA) are precision-medicine assays that include key companion diagnostic biomarkers with therapy claims. The assays detect all classes of alterations, including genomic signatures for microsatellite instability (MSI), tumor mutational burden (TMB), and loss of heterozygosity (LOH), according to the company.

A sequencing-based test utilizing DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens, MI Exome CDx provides qualitative detection of genomic alterations. MI Transcriptome CDx, which received a breakthrough device designation by the FDA in 2019, is a sequencing-based test that utilizes RNA isolated from FFPE tumor tissue specimens to qualitatively detect genomic and transcriptomic alterations, Caris said.

Genetics group guides labs on fetal exome sequencing
Clinical laboratories are advised to have clearly defined turnaround times for fetal exome sequencing and reporting policies for incidental findings and...
Personalis launches Next Dx cancer profiling test
Personalis has announced the launch of its Next Dx comprehensive genomic profiling laboratory-developed test, which is designed for use by oncologists...
Whole exome sequencing not always what it's cracked up to be
Depending on the reporting lab, whole exome sequencing test results may be incomplete and falsely reassuring if negative, according to a small study published...
Study homes in on genetic risk for type 2 diabetes
An exome sequencing study of almost 46,000 people has pinpointed four genes with rare variants that put people at risk for type 2 diabetes, a large team...
Caris gets FDA breakthrough status for companion diagnostic
The U.S. Food and Drug Administration (FDA) has granted breakthrough device status to the MI Transcriptome companion diagnostic test from Caris Life Sciences.

Copyright © 2020

Last Updated mf 4/28/2020 1:15:41 PM